Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX)
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 1 Sep 2017.
- 26 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.